Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDeate-Esophageal01: I-DXd in Pretreated Advanced or Metastatic ESCC
NCT06644781Phase 3Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Mar 2025
- Primary completion
- Jun 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 17
01
Overview
A Phase 3 trial of ifinatamab deruxtecan in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Daiichi Sankyo Co., Ltd.. Started Mar 2025; status: recruiting.
02
Drugs
ifinatamab deruxtecan
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06644781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06644781.